Aquestive Therapeutics Stock Surges 43% Over Complete Response Letter From FDA For Anaphylm NDA

Stock of Aquestive Therapeutics, Inc. (AQST) is soaring about 43 percent on Monday morning trading following its announcement about a Complete Response Letter received from the FDA for the New Drug Application seeking approval of Anaphylm Sublingual Film for the treatment of Type I allergic reactions.Currently, AQST is trading at $4.22, up 42.98 percent, over the previous close of $2.95. The stock opened at $3.79 and has climbed as high as $4.39 so far in today's session. Over the past year, it has traded ...